View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
June 25, 2018

Trovagene starts enrolment in Phase ll trial of PCM-075 and Zytiga

Trovagene has started enrolling patients in a Phase II clinical trial evaluating the safety and effectiveness of PCM-075 in combination with Zytiga (abiraterone acetate) and prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Trovagene has started enrolling patients in a Phase II clinical trial evaluating the safety and effectiveness of PCM-075 in combination with Zytiga (abiraterone acetate) and prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

The development follows an Institutional Review Board (IRB) approval granted by Dana-Farber / Harvard Cancer Center (Dana-Farber) in the US to Trovagene for the trial.

The multi-centre open-label trial is being carried out by Beth Israel Deaconess Medical Center (BIDMC), Dana-Farber, and Massachusetts General Hospital Cancer Center (MGH).

BIDMC Genitourinary Oncology Programme representative Dr David Einstein is the principal investigator of the trial, which will enrol up to 45 patients to orally administer the drug combination.

“Pre-clinical work has identified polo-like kinase 1 as a drug target meriting study in combination with abiraterone.”

Patients will be enrolled with mCRPC who are showing signs of disease progression demonstrated by two increasing prostate-specific antigen (PSA) values separated by at least one week while on abiraterone acetate and prednisone therapy.

The primary efficacy endpoint of the trial includes the proportion of patients achieving disease control after 12 weeks of study treatment, as measured by lack of PSA progression in patients that are showing signs of early progressive disease while currently receiving abiraterone acetate and prednisone.

Dr Einstein said: “Prostate cancer will kill an estimated 29,430 men in the US this year.

“It is clear that resistance to standard therapies continues to be an urgent problem for our patients.

“Pre-clinical work has identified polo-like kinase 1 as a drug target meriting study in combination with abiraterone.”

Trovagene’s PCM-075 is a highly selective adenosine triphosphate (ATP) competitive inhibitor of serine / threonine polo-like-kinase 1 (PLK 1) enzyme, which is over-expressed in a number of hematologic and solid tumour cancers.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena